AT-406 clinical trials
Also written Debio 1143 and Xevinapant.
How each study uses AT-406 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 6
Debiopharm International SA (6) · EMD Serono Research & Development Institute, Inc. (3) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Centre Leon Berard (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · University of Chicago (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · Ascenta Therapeutics (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses AT-406 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT05724602Written as XevinapantHow we know
- Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck CancerTerminatedPhase 1University of ChicagoNCT06110195Written as XevinapantHow we know
- Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)TerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT05386550Written as XevinapantHow we know
- A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)TerminatedPhase 3EMD Serono Research & Development Institute, Inc.NCT04459715Written as Xevinapant (Debio 1143)How we know
- Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)TerminatedPhase 1EMD Serono Research & Development Institute, Inc.NCT06056310Written as XevinapantHow we know
- PK Study of Xevinapant (Debio 1143) in Healthy East Asian ParticipantsCompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05519540Written as Xevinapant (Debio 1143)How we know
- Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck CancerTerminatedPhase 3Groupe Oncologie Radiotherapie Tete et CouNCT05930938Written as XevinapantHow we know
- Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)WithdrawnPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT06463184Written as XevinapantHow we know
- Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck CancerWithdrawnPhase 2ECOG-ACRIN Cancer Research GroupNCT06084845Written as XevinapantHow we know
- Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143CompletedPhase 1/2Debiopharm International SANCT04122625Written as Debio 1143How we know
- Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic AdenocarcinomaCompletedPhase 1Centre Leon BerardNCT03871959Written as DEBIO1143How we know
- Debio 1143-201 Dose-finding and Efficacy Phase I/II TrialCompletedNot applicableDebiopharm International SANCT02022098Written as Debio 1143How we know
- A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based TherapyCompletedPhase 1Debiopharm International SANCT03270176Written as Debio 1143How we know
- A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male ParticipantsCompletedPhase 1Debiopharm International SANCT04962724Written as Xevinapant 200 mg (Oral Solution)How we know
- Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and LymphomasCompletedPhase 1Debiopharm International SANCT01078649Written as Debio 1143 (AT-406)How we know
- Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesTerminatedPhase 1Debiopharm International SANCT01930292Written as Part A: Debio 1143How we know
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)TerminatedPhase 1Ascenta TherapeuticsNCT01265199Written as AT-406 in combination with daunorubicin and cytarabineHow we know
Codes
What other systems call AT-406 · ClinicalTrials.gg INT005857
- UNII (FDA) N65WC8PXDDXEVINAPANTConfirmed FDA, Wikidata
- Wikidata Q27074566AT-406Confirmed FDA, Wikidata
- DrugBank DB16305One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N65WC8PXDD | XEVINAPANT | Confirmed FDA, Wikidata |
| Wikidata | Q27074566 | AT-406 | Confirmed FDA, Wikidata |
| DrugBank | DB16305 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.